Kornimate/medical-research-clean huggingface dataset:
dose, effects and characteristics of pilocarpine

Conditions: Open-angle Glaucoma

Summary: the purpose of this investigation, in which pilocarpine was given in repeated doses, was to evaluate: part i - the effects of different concentrations of pilocarpine hydrochloride on intraocular pressure. part ii -the effects on intraocular pressure of glaucomatous patients to pilocarpine 2% when given once, twice and four daily. in addition, we studied various attributes of the eye which may serve as indicators of responsiveness of individual patients to pilocarpine.

in addition, we studied various attributes of the eye which may serve as indicators of responsiveness of individual patients to pilocarpine.

Eligibility criteria:
inclusion criteria: * primary open-angle glaucoma * primary open-angle glaucoma suspect

Keywords: pilocarpine poag iop concentration frequency primary open-angle glaucoma primary open-angle glaucoma suspect
remineralization potential of mi varnish versus fluoride varnish on white spot lesions in maxillary primary incisors

Conditions: Remineralization Effect of the Varnish on White Spot Lesions

Summary: remineralization effect of cpp-acp and fluoride (mi varnish) versus fluoride varnish on white spot lesions in maxillary primary incisors

early childhood caries (ecc) is a very common and consequential chronic disease affecting young children ( çolak et al., 2013). the prevalence of ecc in egypt is high, it is about (78%) according to the last egyptian report, 2014. ecc begins with white-spot lesions, and caries can progress continuously, leading to complete destruction of the crown. calcium and phosphate ions are more readily lost for children because lower mineralization of deciduous enamel. the disease usually develops very quickly and causes many childhood health problems, such as caries-related toothache and infection. demineralization and remineralization are dynamic processes in caries initiation, progression, and reversal. therefore, regulation of the demineralization- remineralization balance is a key to caries prevention and treatment. the ideal method of increasing remineralization is reconstructing the depleted tissues with hydroxyapatite, which is the same inorganic component as the enamel. fluoride varnishes have been the standard practice for the professional application of fluoride. casien phosphopeptide (cpp) is a sticky protein that binds and stabilizes calcium and phosphate ions in an amorphous state. cpp-acp has been shown to adhere to teeth surfaces.

Eligibility criteria:
inclusion criteria: 1. children with white spot lesions on their incisors. 2. age ranging 3-5 years. 3. good general health. exclusion criteria: 1. chronic use of medications or antibiotics 2. lack of cooperation in the oral examination 3. allergies to milk protein or benzoate preservatives 4. presence of oral soft-tissue lesions or enamel hypoplasia at baseline examination, 5. children who have received a fluoride supplement or professional topical fluoride application at least 3 months before or during the study period. -

Keywords: early childhood caries casein phosphopeptides-amorphous calcium phosphate fluoride remineralization potential varnish
adjuvant radiotherapy for patients with esophageal squamous cell carcinoma after r0 resection

Conditions: Esophageal Cancer

Summary: this retrospective study is exploring the treatment effect and toxicity of adjuvant radiotherapy in patients diagnosed with esophageal squamous cell carcinoma after r0 resection.

surgery is one of the most important curative approaches for esophageal cancer. in real-world clinical practice, over 50% of the patients receiving surgical resection as primary management. for patients treated with surgical resection without adjuvant therapy, the probability of local-regional recurrence ranged from 23.0% to 56.5%, accounting for 55.6%-84.5% of the disease recurrence. once encountering disease recurrence, the subsequent prognosis could be dismal. the median survival time after postoperative disease recurrence ranged from 3 to 8 months. postoperative radiotherapy (port) was one of the potential topical treatment approaches prolonging local-regional recurrence time or moreover, attaining superior disease-free survival (dfs) or overall survival (os) in selected patients. it is essential to identify patients potentially benefit from port. besides, there were few studies evaluating the impact of postoperative radiation dose to survival outcomes in patients receiving port. whether the port-related local-regional recurrence free survival (lrfs) enhancement could convert to os or dfs improvement is still vague. the current study aimed at evaluating the value of port in patients diagnosed with esophageal squamous cell carcinoma after r0 resection.

Eligibility criteria:
inclusion criteria: * kps≥70 * pathologically diagnosis of esophageal cancer * complete resection (r0 resection) exclusion criteria: * diagnosed with other malignancy within 5 years before surgery * encountered recurrence or port-site implantation receiving palliative-intended radiotherapy * diagnosed with adenosquamous carcinoma or basal cell-like carcinoma * treated with port with uncertain radiation dose * treated with port with radiation dose \> 60gy

Keywords: esophageal cancer postoperative radiotherapy adjuvant radiotherapy
nanogen pegfilgrastim (pegcyte) pk/pd clinical study in breast cancer patients

Conditions: Breast Cancer

Summary: breast cancer patients scheduled to receive myelosuppressive chemotherapy (ac regimen) will be enrolled in this study. eligible patients receive single sc injection of pegcyte or neulastim 24 hours after administration of chemotherapy (doxorubicin and cyclophosphamide) in the first cycle (14 days each cycle). blood samples are collected to determine the serum concentration of investigational drugs at specific time points in the first cycle. absolute neutrophil count, cd34+ count, cmax (maximum serum concentration), auc0-t (area under the curve of the plasma concentration time) and tmax (time required to reach cmax) will be calculated from the serum concentration profile


Eligibility criteria:
inclusion criteria: * female patients aged between 18 - 65 years. * patients with histological confirmed primary invasive breast cancer; stage i, ii or iii. * patients had no prior chemotherapy treatments. * patients scheduled to undergo myelosuppressive doxorubicin and cyclophosphamide chemotherapy for 04 cycles, and paclitaxel chemotherapy for the next 04 cycles; patients were available for 14 days of each cycle for the first 03 chemotherapy cycles. * patients with baseline anc ≥ 1.5 x 109/l, plt ≥ 100 x 109/l, hgb ≥ 9 g/dl, wbc ≥ 3,000/ml and albumin ≥ 3.0 g/dl. * performance status as per ecog (eastern cooperative oncology group) score 0, 1 or 2. * willing to give written and signed informed consent exclusion criteria: * patients with prior exposure of g-csf or gm-csf or its pegylated products in clinical development less than 6 months prior to randomization. * myelotoxic concomitant treatment such as chloramphenicol, methotrexate, immunomodulating agents, interferons during 10 days before randomization. * received systemic antibiotic treatment within 72 hours of chemotherapy. * chronic use of corticosteroids, prior bone marrow or stem cell transplant. * patients who had an immediate/ concurrent exposure to radiotherapy or surgery (within 4 weeks). * severe medical disease: cardiovascular, hepatic, renal, pulmonary... * known cases of hematological disease (sickle cell anemia, aml...) * history of hiv positive, active hepatitis. * pregnant and lactating women or patients planning to become pregnant. * known allergic reactions to study medications. * positive to anti-pegfilgrastim antibody test.
the study of the impact of disclosing imaging study information to trial participants

Conditions: Parkinsonian Syndrome; Parkinson

Summary: the overall goal of the study is to evaluate how research participants in parkinson disease studies that include brain imaging with a dopamine transporter ligand choose to receive the imaging data and what is the impact of the imaging data information on the management of their symptoms.

research participants who previously underwent ß-cit imaging will be contacted by the staff at ind to enquire whether they would like to receive their ß-cit scan data. after signing a research participant information and consent form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. those research participants requesting imaging data will be sent their data by ind and may review their data with ind (by phone) and/ or with their study investigator. all research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.

Eligibility criteria:
inclusion criteria: * previous participation in imaging study as described within the protocol exclusion criteria: -

Keywords: parkinson imaging
evaluation of chemotherapy prior to surgery with or without zometa for women with locally advanced breast cancer

Conditions: Breast Neoplasms

Summary: this study is designed to evaluate the impact of zometa on clearance of bone marrow micrometastases; the protective effect on chemotherapy-induced loss of bone mineral density; and quality of life in women undergoing treatment for locally advanced breast cancer.


Eligibility criteria:
inclusion criteria: * newly diagnosed primary invasive ductal or invasive lobular breast adenocarcinoma * tumor classified as clinically large t2 (2-5 cm), t3, t4 or any t with n1, n2 * prior malignancies: limited to curatively treated basal or squamous carcinoma of the skin or history of previous malignancies, treated and now \> 5 years disease free * \>= 18 years of age * normal left ventricular function by echocardiogram or radioventriculogram * karnofsky performance \>= 70 exclusion criteria: * no evidence of distant metastasis present by ct, bone scan, or physical exam * if the bone scan or ct scans demonstrate indeterminate lesions, the nature of these lesions may be further clarified by additional testing such as pet or mri * no current treatment with zometa or other bisphosphonates * no serious functional disorders of the liver or kidneys: * serum creatinine \<=2 * alt/ast/alk phos \<= 1.5 x upper limit of institutional normal. * bili \<= 1.5 x upper limit of institutional normal. * currently not pregnant

Keywords: breast cancer neoadjuvant micrometastasis
tramadol clinical efficiency and tolerance correlated to o-desmethyltramadol/tramadol ratio (clincytram)

Conditions: Pain

Summary: tramadol is a grade ii analgesics as world health organization definition. it can both be an agonist on mu receptors, which provides it a low opioid action, and also be a serotonin-norepinephrine reuptake inhibitor, which act on neuropathic pain. tramadol is metabolized by p450 2d6 cytochrome (cyp2d6) in o-desmethyltramadol (o-dt) which is the most active form on the pharmacologic side (analgesic effect 2 to 4 times more powerful than tramadol itself). in caucasian population, 5 to 10% of patients are genetically qualified as "poor metabolizer phenotype"; this status is correlated to a lower analgesic efficiency compared to "rapid metabolizer". a multicenter study, cytram, is under publication and allowed measurement of blood ratio o-dt/tramadol as a way to know the phenotype of cyp2d6 to detect "poor metabolizer phenotype" status. indeed, blood ratio o-dt/tramadol threshold under 0.1 detects " poor metabolizer phenotype " status for postoperative patients treated by tramadol, with a good sensibility (87,5%) and specificity (83.8%). which impacts for current practice? the next step is to know if this blood ratio is linked to an analgesic efficiency and a good tolerance for tramadol. a "poor metabolizer phenotype" patient would have no benefit of tramadol posology increasing. therefore, phenotype detection, thank to blood ratio, could allow to switch quickly tramadol to another analgesic treatment for "poor metabolizer phenotype" patients. the main objective of the study is to forge a link between o-dt/tramadol ratio and analgesic efficiency. secondary objectives investigate side effects and frequency related to o-dt/tramadol ratio and pain relief, and also impact of cyp2d6 - inhibitor treatments on the blood ratio. if there is a correlation between this blood ratio and treatment efficiency and tolerance, o-dt/tramadol ratio's detection will allow a better adaptation for some treatments metabolized by cyp2d6. therefore, this evolution will contribute to health quality and health safety improvement.


Eligibility criteria:
inclusion criteria: * patients \>18 years old treated by tramadol for at least 48h * tramadol posology between 100 and 400 mg/d (oral treatment) and until 600 mg/d (veinous treatment), recommended dosage * patients with nociceptive pain, definite etiology, combined or not with neuropathic pain * caucasian patient * patient able to give his/her informed consent * patient able to estimate himself/herself pain with pain scale for at least 48h exclusion criteria: * age \< 18 years old * patient with chronic pain (\>3 month) or not definite * tramadol posology \>400 mg/d (oral treatment) or \> 600 mg/d (veinous treatment) * patients with absolute tramadol contraindication * chronic endstage kidney failure antecedent (cl cockcroft \< 10ml/min) and liver failue antecedent * concomitant analgesic treatment, except paracetamol or stopped less than 48h ago * pregnant or breast-feeding patient
a longitudinal study of movement and participation in patients with cerebral palsy

Conditions: Cerebral Palsy

Summary: the primary goal of this study is to establish and evaluate an image-based biomarker for the impaired motor control and sensory information processing present in cerebral palsy (cp) patients

cerebral palsy (cp) may lead to various motor deficits, which further influence the activities and participation. it would be ideal to characterize neural network and motor control model in patients with cp that underlies their clinical behavior by identifying altered neural network and motor control associated with behavioral improvement. the aim of this study is to investigate the brain image and motor control in patients with cp evaluated by multimodal imaging studies utilizing multi-modal techniques and kinematic analysis. this study includes a prospective longitudinal study of patients with cp over one-year. this study will be executed in 3 phases within 3 years: 1st phase (1st years): to establish the multimodal brain images and motor control, and clinical outcomes protocol with a prospective one-year follow-up study in healthy subjects; 2nd phase (2nd years): to establish the brain images and motor control, and clinical outcomes with a prospective one-year follow-up study in older patients with cp; and 3rd phase (3rd years): to establish the brain images and motor control, and clinical outcomes with a prospective one-year follow-up study in younger patients with cp. in a prospective longitudinal study, each participant received 3-times measurements: at the beginning, 6 months later, and one year after the first data collection point

Eligibility criteria:
inclusion criteria: * (1) age: 4-20 y/o (2) good cognition and cooperation (3) healthy participants exclusion criteria: * (1) motor problems (2) neurological, orthopedic, or progressive disorders (3) active medical diseases, such as infection

Keywords: cerebral palsy multi-modal brain techniques mri kinematic motor control
tofacitinib in adult patients with moderate to severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: this is an observational prospective study with two years of follow-up, designed to evaluate the effectiveness of tofacitinib in patients with moderate to severe ulcerative colitis in french clinical practice

to fast is a non-interventional study in france with primary objective to describe the clinical benefit of tofacitinib 1 year after its initiation for the treatment of moderate to severe uc in routine clinical practice. the study will also make it possible to report the clinical benefit 2 years after its initiation, to search for predictors of clinical benefit, improve our understanding of the efficacy of treatment in a real-life setting (in terms of response and speed of response), describe the characteristics of patients starting a treatment by tofacitinib, its real-life patterns of use as well as patient adherence to treatment.

Eligibility criteria:
inclusion criteria: * patients of 18 years old or above * patients with confirmed diagnosis of moderate to severe ulcerative colitis * patients for whom gastroenterologist decides to initiate treatment with tofacitinib as per the french smpc * patients informed about the study procedures and receiving an information letter signed by the investigator exclusion criteria: * patients who have already received tofacitinib treatment before baseline * patients that fulfill any of the contrindications according to the latest version of the smpc

Keywords: ulcerative colitis, tofacitinib, france, real world data
evaluation of butyrate effect on diarrhea

Conditions: Antibiotic-associated Diarrhea

Summary: the goal of this clinical trial is to evaluate the effects of a food supplement containing calcium butyrate, vitamin d, and zinc, on the variation of intestinal microbiota and prevention of antibiotic-induced diarrhea, in individuals who have been prescribed antibiotic therapy. the main questions it aims to answer is: does dibuzin improve the microbiota composition in patients undergoing antibiotic treatment? does dibuzin prevent antibiotic-induced diarrhea? participants will: - take 2 capsules/day of dbz (1 /morning and 1 /evening, away from meals) for 14 gg. -visit the clinic two times ( t0 and at the end), collect three fecal samples, and fill out two questionnaires 3 times.

antibiotic-associated diarrhea (aad) is an important morbidity resulting from antibiotic use. aad is more than a bothersome adverse event of antibiotic treatment; it is associated with prescription noncompliance and overuse of second-line antibiotics. any antibiotic could potentially cause aad, but broad-spectrum antibiotics that predominantly target anaerobes and are poorly absorbed, have a higher aad incidence. alterations in the diversity of the gut microbiota are believed to underlie the development of antibiotic-associated diarrhea, likewise, micronutrient deficiencies can exacerbate both barrier leak and morbidity. the use of scfas, such as butyrate, along with vitamin d and zinc, each possessing unique properties that contribute to enhancing the microbiota, controlling inflammation, and promoting a healthy intestinal barrier, may be beneficial in the prevention of aad. the proposed dietary supplement contains butyrate, vitamin d, and zinc, and is presented as a potential product useful in the prevention of aad.

Eligibility criteria:
inclusion criteria: * subjects undergoing antibiotic therapy * subjects capable of conforming to the study protocol * subjects who have given their free and informed consent exclusion criteria: * subjects with untreated food intolerance, i.e. remaining symptomatic despite the withdrawal of the suspected food * subjects who become unable to conform to protocol * subjects who are continuously taking contact laxatives subjects who are treated with pre/probiotics

Keywords: antibiotics, microbiota, diarrhea
effect of prebiotics on hyperuricemia

Conditions: Subjects With Hyperuricemia

Summary: hyperuricemia is a major risk factor for many chronic diseases. recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of hyperuricemia. animal studies have demonstrated that administration of prebiotics help delay the progression of hyperuricemia through several mechanisms. this trial aims to examine its protective effect in humans.

hyperuricemia is a major risk factor for many chronic diseases. recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of hyperuricemia. animal studies have demonstrated that administration of prebiotics help delay the progression of hyperuricemia through several mechanisms such as reduction in endotoxemia, and enhanced production of short-chain fatty acids. however, whether administration of prebiotics also has a protective effect in subjects with hyperuricemia remain unknown.

Eligibility criteria:
inclusion criteria: * local residents aged between 18-65 years old; * stable weight (\<5% weight change over last 3 months); * fasting uric acid was \> 420μmol/l for male and \> 360μmol/l for female on two different days * those who have never taken uric acid lowering drugs or have stopped taking uric acid lowering drugs for at least four weeks; * absence of any diet or medication that might interfere with uric acid metabolism and gut microbiota, especially antibiotics and probiotics at least 4 weeks before recruitment. exclusion criteria: * acute illness or evidence of any acute or chronic inflammatory of infective diseases; * participation in regular diet program more than 2 times per week in the latest 3 months prior to recruitment; * mental illness rendering them unable to understand the nature, scope, and possible consequences of the study. * women of childbearing age who are pregnant, breast-feeding or preparing for pregnancy; patients who had surgery within the past six months or planned surgery during the trial period
the efficacy of solifenacin succinate as adjuvant therapy for urinary tract infection in females

Conditions: Urinary Tract Infection

Summary: the efficacy of solifenacin succinate 5 mg as adjuvant therapy and levofloxacin (500 mg) for short-term treatment to reduce symptoms in patients with symptomatic non complicated urinary tract infection in females.


Eligibility criteria:
inclusion criteria: * females (18-65 years old) * dysuria in symptomatic non complicated urinary tract infection exclusion criteria: * pediatric patients (\< 18 years old) * geriatric patients (\> 65 years old) * pregnant patients * patients with complicated urinary tract infection * sexually transmitted infections * patients with pathological abnormalities in the urinary bladder, including stone/mass * catheter-mounted * neurological diseases/disorders * patients with allergy/hypersensitivity with levofloxacin/solifenacin

Keywords: female age 18-65 years storage symptoms clinical urinary tract infection non complicated